Table 3 Distribution of distinct BM-associated populations as identified by the NGF antibody combination (version 5) and percentages of MRD− and MRD+ cases with decreased levels
BM-associated cell population (phenotypea) | Normal BM range (n=16), hemodiluted BM cutoff | % of cases with low levels | NGF MRD − patients showing disease progression TOTAL | ||
|---|---|---|---|---|---|
MRD − | MRD + | Case 1 | Case 2 | ||
% Mast cells (CD117hi, CD45+, CD81dim, CD38+, SSC/FSCint−hi) | 0.006% (0.002–0.03%) | 10% | 5% | 0.0017% | 0.0006% |
% NRBC (SSC/FSClo, all markers−) | 6.4% (2–11.5%) | 3% | 1% | 8% | 5% |
% CD19− nPC (CD38hi, CD138+, CD45−/+, CD56−/+, CD81−/+, CD27+, FSC/SSCint) | 0.05% (0.003–0.2%) | 14% | 14% | 0.0038% | 0.0036% |
% CD27+ B Cell precursors (CD19+; CD38++, CD45dim, CD81++, CD27+, CyIg−, FSC/SSClo) | 0.08% (0.004–0.4%) | 12% | 11% | 0.0001% | 0.003% |
% CD27− B Cell precursors (CD19+; CD38++, CD45dim, CD81++, CD27−, CyIg−, FSC/SSClo) | 0.4% (0.05–2.2%) | 11% | 13% | 0.001% | 0.01 |
% Mature B cells (CD19+; CD38+, CD45dim/+, CD81+, CD27−/+, CyIg+, FSC/SSClo) | 1.6% (0.6–3.5%) | 26% | 23% | 0.1% | 0.1% |
% Myeloid precursors (CD117+, CD45dim, CD38dim/+; CD81+, SSC/FSCint) | 1.8% (0.2–3.6%) | 8% | 8% | 0.3% | 0.3% |
% Endothelial and mesenchymal cells (CD81hi, CD45−, SSC/FSCint/hi) | 0.01% (0.0005–0.08%) | 1% | 0% | 0.02% | 0.02% |
